As result of this change the financial impact of the contract will be accelerated in 2017. Consequently the Board anticipates that results for 2017 will now be ahead of its current expectations albeit with a corresponding effect on 2018.
Back to All News
All Market News
Other Market News
AstraZeneca Releases Enhertu Update
B.P. Marsh – Special Dividend Declaration
M.P. Evans Announces Acquisition
Henderson International Trust – Publication of Circular
GSK Releases Arexvy Update
GSK Releases Penmenvy Update
Sign up for our Stock News Highlights
Delivered to your inbox every Friday